Giuseppe Aprile
Giuseppe Aprile
Department of Oncology, Vicenza, Italy
Verified email at aulss8.veneto.it
Title
Cited by
Cited by
Year
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3 …
YJ Bang, E Van Cutsem, A Feyereislova, HC Chung, L Shen, A Sawaki, ...
The Lancet 376 (9742), 687-697, 2010
58452010
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo …
CS Fuchs, J Tomasek, CJ Yong, F Dumitru, R Passalacqua, C Goswami, ...
The Lancet 383 (9911), 31-39, 2014
17712014
Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease
K Qureshi, GA Abrams
World journal of gastroenterology: WJG 13 (26), 3540, 2007
698*2007
Ischemia/reperfusion injury and cardioprotective mechanisms: role of mitochondria and reactive oxygen species
MG Perrelli, P Pagliaro, C Penna
World journal of cardiology 3 (6), 186, 2011
3722011
ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction …
YJ Bang, E Van Cutsem, A Feyereislova, HC Chung, L Shen, A Sawaki, ...
Lancet 376 (9742), 687-697, 2010
2982010
Non-invasive diagnosis of advanced fibrosis and cirrhosis
S Sharma, K Khalili, GC Nguyen
World journal of gastroenterology: WJG 20 (45), 16820, 2014
196*2014
Clinical advances in the development of novel VEGFR2 inhibitors
C Fontanella, E Ongaro, S Bolzonello, M Guardascione, G Fasola, ...
Annals of translational medicine 2 (12), 2014
1902014
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis
C Cremolini, M Di Bartolomeo, A Amatu, C Antoniotti, R Moretto, ...
Annals of oncology 26 (10), 2092-2097, 2015
1552015
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
E Valtorta, C Martino, A Sartore-Bianchi, F Penaullt-Llorca, G Viale, ...
Modern Pathology 28 (11), 1481-1491, 2015
1462015
Role of mammography, ultrasound and large core biopsy in the diagnostic evaluation of papillary breast lesions
F Puglisi, C Zuiani, M Bazzocchi, F Valent, G Aprile, B Pertoldi, ...
Oncology 65 (4), 311-315, 2003
1152003
REGARD Trial Investigators Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised …
CS Fuchs, J Tomasek, CJ Yong, F Dumitru, R Passalacqua, C Goswami, ...
Lancet 383 (9911), 31-39, 2014
1132014
Prognostic role of Ape/Ref-1 subcellular expression in stage I-III breast carcinomas
F Puglisi, F Barbone, G Tell, G Aprile, B Pertoldi, C Raiti, MR Kelley, ...
Oncology reports 9 (1), 11-17, 2002
1132002
BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection
M Schirripa, F Bergamo, C Cremolini, M Casagrande, S Lonardi, G Aprile, ...
British journal of cancer 112 (12), 1921-1928, 2015
1122015
Fatigue: a main component of anemia symptomatology
A Sobrero, F Puglisi, A Guglielmi, O Belvedere, G Aprile, M Ramello, ...
Seminars in oncology 28, 15-18, 2001
1102001
Acute-on-chronic liver failure: Pathogenesis, prognostic factors and management
S Blasco-Algora, J Masegosa-Ataz, ML Gutiérrez-García, S Alonso-López, ...
World journal of gastroenterology 21 (42), 12125, 2015
107*2015
New frontiers in the pathobiology and treatment of cancer regimen-related mucosal injury
M Cinausero, G Aprile, P Ermacora, D Basile, MG Vitale, V Fanotto, ...
Frontiers in pharmacology 8, 354, 2017
1042017
Prognostic significance of Ape1/ref-1 subcellular localization in non-small cell lung carcinomas
DI cARLA
Anticancer research 21, 4041-4050, 2001
1032001
Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical …
C Cremolini, D Rossini, E Dell’Aquila, S Lonardi, E Conca, M Del Re, ...
JAMA oncology 5 (3), 343-350, 2019
1012019
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the …
L Fornaro, S Lonardi, G Masi, F Loupakis, F Bergamo, L Salvatore, ...
Annals of oncology 24 (8), 2062-2067, 2013
982013
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild‐type KRAS advanced biliary tract cancer: A randomized phase 2 …
F Leone, D Marino, S Cereda, R Filippi, C Belli, R Spadi, G Nasti, ...
Cancer 122 (4), 574-581, 2016
932016
The system can't perform the operation now. Try again later.
Articles 1–20